Details for Patent: 8,088,781

Title:	Inhibitors of brutons tyrosine kinase
Abstract:	Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
Inventor(s):	Honigberg; Lee (San Francisco, CA), Verner; Erik (Belmont, CA), Pan; Zhengying (Austin, TX), Mody; Tarak D. (Sunnyvale, CA)
Assignee:	Pharmacyclics, Inc. (Sunnyvale, CA)
Filing Date:	Jan 20, 2009
Application Number:	12/356,498
Claims:	1. An inhibited tyrosine kinase comprising an irreversible BTK inhibitor having a covalent bond to a cysteine residue of a Bruton's tyrosine kinase (Btk). 2. The inhibited tyrosine kinase of claim 1, wherein the covalent bond is formed between a portion of a Michael acceptor moiety on the inhibitor and a portion of a cysteine residue of a Bruton's tyrosine kinase (Btk). 3. The inhibited tyrosine kinase of claim 2, wherein the Michael acceptor moiety is an acrylamide, vinyl sulfonamide or propargylamide. 4. The inhibited tyrosine kinase of claim 1, wherein the inhibitor has a covalent bond to cysteine residue 481. 5. The inhibited tyrosine kinase of claim 1, wherein the Bruton's tyrosine kinase is activated. 6. The inhibited tyrosine kinase of claim 1, wherein the inhibited tyrosine kinase has the structure: ##STR00056## wherein L.sub.a is O or S; Ar is an unsubstituted phenyl; Y is a 4-, 5-, 6-, or 7-membered cycloalkyl ring, or Y is azetidinyl, pyrrolidinyl, piperidinyl, or azepanyl; Z is C(.dbd.O), OC(.dbd.O), NHC(.dbd.O), S(.dbd.O).sub.x, or NHS(.dbd.O).sub.x, where x is 2; R.sub.8 is H; R.sub.7 is H, unsubstituted C.sub.1-C.sub.4 alkyl, C.sub.1-C.sub.6alkoxyalkyl, C.sub.1-C.sub.8alkylaminoalkyl, or C.sub.1-C.sub.4alkyl(phenyl); or R.sub.7 and R.sub.8 taken together form a bond; R.sub.6 is H, unsubstituted C.sub.1-C.sub.6alkoxyalkyl, C.sub.1-C.sub.8alkylaminoalkyl, or C.sub.1-C.sub.4alkyl(phenyl); indicates the point of attachment between the inhibitor and the tyrosine kinase. 7. The inhibited tyrosine kinase of claim 6, wherein the inhibitor has a covalent bond to a cysteine residue on the tyrosine kinase. 8. The inhibited tyrosine kinase of claim 7, wherein the inhibitor is has a covalent bond to cysteine residue 481.